Ophthalmology’s top five retina articles from July
July was a busy month for retina news, including coverage of the virtual American Society of Retina Specialists meeting.
Here are the most-read retina/vitreous articles from July.
Ranibizumab, delayed photocoagulation ‘can be used in practice immediately’
Intravitreal ranibizumab with delayed laser photocoagulation effectively treated severe zone I and posterior zone II retinopathy of prematurity. Read more.
Second phase 3 trial of Zimura underway
The first patient has been dosed in a second phase 3 clinical trial of Zimura for the treatment of geographic atrophy secondary to age-related macular degeneration. Read more.
Real-world study shows long-term safety, efficacy of Iluvien in DME
Real-world long-term study outcomes showed sustained safety and efficacy of Iluvien in patients with diabetic macular edema. Read more.
Archway demonstrates PDS outcomes equivalent to ranibizumab
Phase 3 results of the Archway trial show patients with neovascular age-related macular degeneration treated with the Port Delivery System with ranibizumab experienced equivalent vision outcomes compared with patients treated with ranibizumab. Read more.
Increasing dose of aflibercept may be beneficial in refractory AMD
Patients with refractory neovascular age-related macular degeneration were more likely to experience greater decreases in central foveal thickness when treated with higher doses of aflibercept. Read more.